ANZCTR - Registration

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers

Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04534725

Registration number

NCT04534725

Ethics application status

Date submitted

30/08/2020

Date registered

1/09/2020

Date last updated

24/08/2023

Titles & IDs

Public title

COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial;

Scientific title

COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial; C-SMART Study.

Secondary ID [1]

Peter Mac ID 20/135

Universal Trial Number (UTN)

Trial acronym

C-SMART

Linked study record

Health condition

Health condition(s) or problem(s) studied:

Cancer

Covid19

Respiratory Viral Infection

Condition category

Condition code

Infection

Other infectious diseases

Respiratory

Other respiratory disorders / diseases

Intervention/exposure

Study type

Interventional

Description of intervention(s) / exposure

Treatment: Drugs - Interferon alfa
Treatment: Drugs - Selinexor
Treatment: Drugs - Lenzilumab

Experimental: prophylaxis - This study arm (arm 1) is evaluating the effect of interferon-alpha on the incidence of COVID-19 infection in cancer patients with no COVID-19 infection or no known COVID-19 positive contacts.

Participants in this study arm are randomly allocated (by chance) to one of two groups. One group will receive daily interferon-alpha intranasal spray for 3 months while the other group will receive a daily placebo intranasal spray for 3 months.

Participants will be followed during the 3-month treatment for incidence of COVID-19 and other respiratory infections.

Experimental: Post-Exposure Prophylaxis - This study arm (arm 2) is evaluating the effect of interferon-alpha on the incidence of COVID-19 infection in cancer patients with confirmed exposure to COVID-19 virus.

Participants in this study arm are randomly allocated (by chance) to one of two groups. One group will receive daily interferon-alpha intranasal spray for 7 days (at a higher dose than arm 1) while the other group will receive a daily placebo intranasal spray for 7 days

Participants will be followed for 28 days for incidence of COVID-19 and other respiratory infections.

Experimental: Moderate COVID-19 infection - This study arm (arm 3) is evaluating the effect of Selinexor on the incidence of COVID-19 infection in cancer patients with moderate COVID-19 infection.

Participants in this study arm are randomly allocated (by chance) to one of two groups. One group will receive oral Selinexor 3 times a week for 2 weeks while the other group will receive oral placebo 3 times a week for 2 weeks

Participants will be followed for 60 days to assess effectiveness and safety.

Experimental: Severe COVID-19 infection - This study arm (arm 4) is evaluating the effect of Lenzilumab on the treatment of COVID-19 infection in cancer patients with severe COVID-19 infection.

Participants in this study arm are randomly allocated (by chance) to one of two groups. One group will receive intravenous Lenzilumab over 24 hours while the other group will receive placebo intravenously over 24 hours.

Participants will be followed for 60 days to assess effectiveness and safety.

Treatment: Drugs: Interferon alfa
intranasal spray

Treatment: Drugs: Selinexor
oral tablet

Treatment: Drugs: Lenzilumab
intravenous infusion

Intervention code [1]

Treatment: Drugs

Comparator / control treatment

Control group

Outcomes

Primary outcome [1]

Incidence of COVID-19 in cancer patients using interferon-alpha as prophylaxis without known positive contact with COVID-19 (COVID-19 confirmed by qPCR from respiratory swab)

Timepoint [1]

3 months from baseline.

Primary outcome [2]

incidence of any upper or lower community acquired respiratory viral infection assessed using local standard of care testing

Timepoint [2]

3 months from baseline.

Primary outcome [3]

incidence of COVID-19 when Interferon alpha is given as post-exposure prophylaxis with a known positive contact or exposure with COVID-19. COVID-19 confirmed by qPCR from respiratory swab .

Timepoint [3]

28 days from baseline

Primary outcome [4]

incidence of any upper or lower community acquired respiratory viral infection assessed using local standard of care testing

Timepoint [4]

28 days from baseline

Primary outcome [5]

incidence of death and/or need for invasive or non-invasive ventilation. assessed using medical records

Timepoint [5]

60 days from baseline

Primary outcome [6]

time to clinical improvement or discharge from hospital assessed using medical records

Timepoint [6]

28 days from baseline

Secondary outcome [1]

ARM 1: Duration of acute respiratory/ILI symptoms in case of confirmed respiratory infection during the study period. Assessed using patient symptom Diary PRO tool

Timepoint [1]

120 days from baseline

Secondary outcome [2]

ARM 1: Time to diagnosis of COVID-19 in case of confirmed COVID-19 diagnosed during the study period (days). Assessed using patient medical records

Timepoint [2]

120 days from baseline

Secondary outcome [3]

ARM 1: Time to diagnosis of other respiratory viral infection in case of confirmed other respiratory viral infection diagnosed during the study period (days). assessed using patient medical records

Timepoint [3]

120 days from baseline

Secondary outcome [4]

ARM 1: Illness severity in case of confirmed COVID-19 diagnosed during the study period using WHO clinical progression scale

Timepoint [4]

120 days from baseline

Secondary outcome [5]

ARM 1: Incidence of unplanned all-cause hospital admission during the study period. assessed using medical records

Timepoint [5]

120 days from baseline

Secondary outcome [6]

ARM 1: Incidence of unplanned infection-related hospital admission during the study period. assessed using medical records

Timepoint [6]

120 days from baseline

Secondary outcome [7]

ARM 1: Incidence of sero-conversion of SARS-CoV-2 at the end of the study period. assessed using qPCR

Timepoint [7]

120 days from baseline

Secondary outcome [8]

ARM 1: Incidence of death from any cause during the study period. assessed using patient medical records

Timepoint [8]

120 days from baseline

Secondary outcome [9]

ARM 1: Incidence of testing for COVID-19 during the study period. assessed using medical records

Timepoint [9]

120 days from baseline

Secondary outcome [10]

ARM 2 Duration of acute respiratory symptoms in case of confirmed COVID-19 diagnosed during the study period. assessed with PRO and medical records.

Timepoint [10]

28 days from baseline

Secondary outcome [11]

ARM 2: Time to diagnosis of COVID-19 in case of confirmed COVID-19 diagnosed during the study period (days). assessed using medical records

Timepoint [11]

28 days from baseline

Secondary outcome [12]

ARM 2: Illness severity in case of confirmed COVID-19 diagnosed during the study period. assessed using WHO clinical progression scale.

Timepoint [12]

28 days from baseline

Secondary outcome [13]

ARM 2: Incidence of unplanned all-cause hospital admission during the study period. assessed using medical records.

Timepoint [13]

28 days from baseline

Secondary outcome [14]

ARM 2: Incidence of unplanned infection-related hospital admission during the study period. assessed using medical records

Timepoint [14]

28 days from baseline

Secondary outcome [15]

ARM 2: Incidence of seroconversion of SARS-CoV-2 at the end of the study period. assessed using qPCR.

Timepoint [15]

28 days from baseline

Secondary outcome [16]

ARM 2: Incidence of testing for COVID-19 during the study period assessed using medical records

Timepoint [16]

28 days from baseline

Secondary outcome [17]

ARM 3: Time to clinical improvement assessed using medical records.

Timepoint [17]

60 days from baseline

Secondary outcome [18]

ARM 3: Illness severity of COVID-19, defined as the maximal score on the World Health Organization (WHO)'s clinical progression ordinal scale

Timepoint [18]

60 days from baseline

Secondary outcome [19]

ARM 3: change to clinical condition assessed with Karnofsky Performance score

Timepoint [19]

60 days from baseline

Secondary outcome [20]

ARM 3: Time to progression to severe COVID-19, defined by WHO ordinal scale

Timepoint [20]

60 days from baseline

Secondary outcome [21]

ARM 3: Time to all-cause mortality

Timepoint [21]

60 days from baseline

Secondary outcome [22]

ARM 3:Duration of hospitalisation assessed using medical records

Timepoint [22]

at discharge or day 60 whichever is sooner

Secondary outcome [23]

ARM 3: Duration of COVID-19 symptoms assessed using patient reported symptom diary.

Timepoint [23]

60 days from baseline

Secondary outcome [24]

ARM 3: Duration of oxygen supplementation (days). assessed using medical records.

Timepoint [24]

60 days from baseline

Secondary outcome [25]

ARM 3: change in nasopharyngeal SARS-CoV-2 viral load shedding (assessed via qPCR)

Timepoint [25]

60 days from baseline

Secondary outcome [26]

ARM 3: Safety and tolerability of selinexor using relevant medical records

Timepoint [26]

60 days from baseline

Secondary outcome [27]

ARM 3: incidence of changes in blood results relevant to clinical improvement assessed using medical records

Timepoint [27]

60 days from baseline

Secondary outcome [28]

ARM 4: Incidence of all cause death by day 28 and 60

Timepoint [28]

day 28 from baseline and day 60 from baseline

Secondary outcome [29]

ARM 4: Time to all-cause mortality

Timepoint [29]

any time up to 60 days from baseline

Secondary outcome [30]

ARM 4: Illness severity of COVID-19, defined as the maximal score on the World Health Organization (WHO)'s clinical progression ordinal scale

Timepoint [30]

any time up to 60 days from baseline

Secondary outcome [31]

ARM 4: Incidence of ARDS assessed using medical records

Timepoint [31]

any time up to 60 days from baseline

Secondary outcome [32]

ARM 4: incidence of HLH. assessed using medical records

Timepoint [32]

any time up to 60 days from baseline

Secondary outcome [33]

ARM 4: Duration of hospitalisation. assessed using hospital medical records.

Timepoint [33]

at discharge or by day 60 whichever is sooner

Secondary outcome [34]

ARM 4: Proportion discharged from hospital. assessed using medical records

Timepoint [34]

at discharge

Secondary outcome [35]

ARM 4: Incidence of mechanical ventilation up to day 28. assessed using medical records

Timepoint [35]

any time up day 28 from baseline

Secondary outcome [36]

ARM 4: Ventilator-free days and proportion who did not receive invasive mechanical ventilation. assessed using medical records

Timepoint [36]

any time up to 60 days from baseline

Secondary outcome [37]

ARM 4: Organ failure free days and proportion who did not develop organ failure. assessed using medical records.

Timepoint [37]

any time up to 60 days from baseline

Secondary outcome [38]

ARM 4: Incidence and duration of ICU admission. assessed using medical records

Timepoint [38]

at discharge or by day 60 from baseline.

Secondary outcome [39]

ARM 4: incidence and duration of supplemental oxygen use. assessed using medical records

Timepoint [39]

any time up to 60 days from baseline

Secondary outcome [40]

ARM 4: Time to clinical improvement defined as National Early Warning Score 2 (NEWS2) of <2 maintained for 24 hours.

Timepoint [40]

any time up to 60 days from baseline

Secondary outcome [41]

ARM 4: incidence of non-invasive ventilation. assessed using medical records

Timepoint [41]

any time up to 60 days from baseline

Secondary outcome [42]

ARM 4: number of participants alive and off oxygen at day 60. assessed using medical records.

Timepoint [42]

any time up to 60 days from baseline

Secondary outcome [43]

ARM 4: proportion of participants who had improved oxygenation for >48 hours. assessed using medical records

Timepoint [43]

any time up to 28 days from baseline

Secondary outcome [44]

ARM 4: Incidence of adverse events based on the national cancer institute CTCAE v5. Assessed using medical records

Timepoint [44]

any time up to day 28 from baseline.

Secondary outcome [45]

ARM 4: incidence of SAEs based on NCI CTCAE v5 assessed using medical records

Timepoint [45]

any time up to 28 days from baseline.

Secondary outcome [46]

ARM 4: change in nasopharyngeal SARS-CoV-2 viral load shedding. assessed using qPCR.

Timepoint [46]

any time up to day 60 from baseline

Eligibility

Key inclusion criteria

* ARM 1:

1. Age equal to or greater than 18 years old
2. Any haematological or solid tumour
3. Signed written and verbal informed consent
4. Willingness to inform the study nurse/co-ordinator of COVID-19 testing
5. Willingness to perform a self-collect nose/throat swab

ARM 2

1. Age equal to or greater than 18 years old.
2. Any haematological or solid tumour
3. Signed written and verbal informed consent
4. Have been exposed to a known COVID-19 case within the last 72 hours, defined by the current Department of Health and Human services such as household contact, 15 minutes of face to face exposure, 2 hours in close space.
5. Willingness to inform the study nurse/co-ordinator of COVID-19 testing
6. Willingness to perform a self-collect nose/throat swab

ARM 3 1. Age equal to or greater than 18 years of age. 2. Any haematological or solid tumour 3. Current or within the last 12 months received cancer related treatment such as chemotherapy, radiotherapy or targeted small molecule, cellular therapy or immune-modulating therapy 4. Signed written and verbal informed consent 5. Laboratory confirmation of SARS-CoV-2 by PCR as per local laboratory assays 6. Hospitalised 7. Symptoms of COVID-19 such as:

1. Fever equal to or greater than 38 degrees Celsius OR
2. Tachypnoea respiratory rate equal to or greater than 20 breaths/min OR
3. Pulse Oxygen saturation (SpO2) equal to or less than 94% 8. Concurrent standard of care antimicrobials, antivirals are allowed. 9. Female and male patients of child bearing potential will use highly effective contraception. In female child bearing potential participants a negative urine pregnancy test will be required.

ARM 4
1. Age equal to or greater than 18 years of age.
2. Any haematological or solid tumour
3. Current or within the last 12 months received cancer related treatment such as chemotherapy, radiotherapy or targeted small molecule, cellular therapy or immune-modulating therapy
4. Signed written and verbal informed consent by participant or proxy capable of giving consent
5. Laboratory virological confirmation of SARS-CoV-2 by PCR as per local laboratory assays and COVID-19 diagnosis prior to randomisation
6. Hospitalised but has not required mechanical ventilation
7. Pneumonia diagnosed by chest x-ray or computed tomography (CT) revealing infiltrates consistent with pneumonia and SpO2 equal to or less than 94% on room air or requires low-flow oxygen supplementation or requires high-flow oxygen supplementation or non-invasive positive pressure ventilation (NIPPV).
8. Has not participated in other clinical trials for COVID-19 using an immunomodulating monoclonal antibody or kinase inhibitor. Note that participants on dexamethasone, corticosteroids, remdesivir, convalescent plasma and/or hydroxychloroquine with or without azithromycin are not excluded from the study. Agents that have received emergency use authorization and/or are considered by the study site to be standard treatment at the institution for COVID-19 are permitted provided the agent is not an immunomodulating monoclonal antibody or kinase inhibitor. Participation in clinical trials with remdesivir or convalescent plasma is permitted provided that all other eligibility criteria are met.
9. Females of childbearing potential must have a negative serum or urine pregnancy test at screening/baseline. Women of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for 5 months following their last dose of study drug.

Minimum age

18 Years

Maximum age

No limit

Sex

Both males and females

Can healthy volunteers participate?

Key exclusion criteria

* ARM 1

1. Previous diagnosis of COVID-19 (microbiologically proven, either symptomatic or asymptomatic)
2. Have been exposed to a known COVID-19 case within the last 72 hours, defined by the current Department of Health and Human services such as household contact, 15 minutes of face to face exposure, 2 hours in close space.
3. Any contra-indication to intra-nasal IFN-a such as severe nasal bleeding requiring intervention, nasal malignancy, nasal deformity, radiotherapy to the nasopharynx and/or oropharynx
4. Pregnant or breast-feeding women, or women who wish to become pregnant during the course of the study
5. Participant unable to return for regular follow-up
6. Life expectancy of less than 4 months
7. Participant already included in another intervention study on the prevention of COVID-19
8. Currently unwell with influenza-like symptoms - if participant is found to be COVID-19 negative and becomes asymptomatic, they can be reconsidered for participation

ARM 2
1. Previous diagnosis of COVID-19 (microbiologically proven, either symptomatic or asymptomatic)
2. Any contra-indication to intra-nasal IFN-a such as severe nasal bleeding requiring intervention, nasal malignancy, nasal deformity, radiotherapy to the nasopharynx and/or oropharynx
3. Pregnant or breast-feeding women, or women who wish to become pregnant during the course of the study
4. Patient unable to return for follow-up
5. Life expectancy of less than 1 month
6. Patient already included in another intervention study on the prevention of COVID-19
7. Currently unwell with influenza-like symptoms

ARM 3
1. Unable to take oral medication
2. Any known allergic reactions to selinexor or concomitant medication-related contra-indications to selinexor.
3. Severe critical COVID-19 infection defined as:

1. Requiring invasive or non-invasive mechanical ventilation, ECMO
2. Anticipated unlikely to survive within 48 hours
4. In the opinion of the investigator and primary oncologist, participation in the study would not be in the best interests of the participant
5. Severe renal impairment defined as creatinine clearance (CrCL) < 20ml/min as calculated using the Cockcroft Gault formula
6. Severe hepatic impairment defined as aspartate transaminase (AST) or alanine transaminase (ALT) > 5 x upper limit of normal (ULN)

ARM 4

1. Invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) 2. History of pulmonary alveolar proteinosis (PAP). 3. Women of childbearing potential who are pregnant or breastfeeding. 4. Known hypersensitivity to lenzilumab or any of its components. 5 .Use of any FDA-approved anti-IL-6 therapy (eg. tocilizumab, sarilumab, siltukimab), anti-IL-1 therapy (eg. anakinra, canakinumab) or kinase inhibitor (eg.baracitinib, ibrutinib, acalabrutinib) therapy to treat COVID-19 within 8 weeks prior to randomization. Any live vaccine within 8 weeks prior to randomisation. Note that subjects receiving other FDA-approved immunomodulators to treat underlying autoimmune disorders such as rheumatoid arthritis, psoriasis, ankylosing spondylitis, asthma, chronic obstructive pulmonary disease, atopic dermatitis, multiple sclerosis, etc. would not be excluded. Participants on corticosteroids or dexamethasone are not excluded from the study. Note: Participants on convalescent plasma, remdesivir and/or hydroxychloroquine with or without azithromycin are not excluded from the study.

6. Use of GM-CSF agents (e.g., sargramostim) within 8 weeks prior to randomisation.

7. Expected survival < 24h in the opinion of the investigator. 8. Any condition that, in the opinion of the investigator, is likely to interfere with the safety and efficacy of the study treatment or puts the subject at unacceptably high risk from the study.

9. Participation in another interventional study of COVID-19

Study design

Purpose of the study

Treatment

Allocation to intervention

Randomised controlled trial

Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)

Methods used to generate the sequence in which subjects will be randomised (sequence generation)

Masking / blinding

Blinded (masking used)

Who is / are masked / blinded?

The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data

Intervention assignment

Other

Other design features

Phase

Phase 3

Type of endpoint/s

Statistical methods / analysis

Recruitment

Recruitment status

Completed

Data analysis

Reason for early stopping/withdrawal

Other reasons

Date of first participant enrolment

Anticipated

Actual

17/12/2020

Date of last participant enrolment

Anticipated

Actual

Date of last data collection

Anticipated

Actual

19/04/2023

Sample size

Target

Accrual to date

Final

441

Recruitment in Australia

Recruitment state(s)

NSW,VIC

Recruitment hospital [1]

Westmead Hospital - Westmead

Recruitment hospital [2]

St Vincent's Hospital - Fitzroy

Recruitment hospital [3]

Peter MacCallum Cancer Centre - Melbourne

Recruitment hospital [4]

Royal Melbourne Hospital - Melbourne

Recruitment hospital [5]

Austin Health - Melbourne

Recruitment postcode(s) [1]

2145 - Westmead

Recruitment postcode(s) [2]

3065 - Fitzroy

Recruitment postcode(s) [3]

3000 - Melbourne

Recruitment postcode(s) [4]

3052 - Melbourne

Recruitment postcode(s) [5]

3084 - Melbourne

Funding & Sponsors

Primary sponsor type

Other

Name

Peter MacCallum Cancer Centre, Australia

Address

Country

Ethics approval

Ethics application status

Summary

Brief summary

A multi-centre Australian trial with four arms aims to evaluate several different immune modulating drugs for prevention and treatment of COVID-19 specifically in the cancer population.

ARM 1 is evaluating the effect of interferon-alpha (vs placebo) on the incidence of COVID-19 infection in cancer patients with no COVID-19 infection or no known COVID-19 positive contacts.

ARM 2 is evaluating the effect of interferon-alpha (vs placebo) on the incidence of COVID-19 infection in cancer patients with confirmed exposure to COVID-19 virus.

ARM 3 is evaluating the effect of Selinexor (vs placebo) on the incidence of COVID-19 infection in cancer patients with moderate COVID-19 infection.

ARM 4 is evaluating the effect of Lenzilumab (vs placebo) on the treatment of COVID-19 infection in cancer patients with severe COVID-19 infection.

Participants may become eligible and transition to different arms and treatments if they become exposed to COVID-19 or are hospitalised with an active moderate/severe COVID-19 infection.

It is hoped this research will provide insight into the best practice for prevention and treatment of COVID-19 in cancer patients as emerging standard of care measures are not always suitable to this especially vulnerable population.

Trial website

https://clinicaltrials.gov/study/NCT04534725

Trial related presentations / publications

Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, Khosravi Z, Popp M, Neidhardt M, Piechotta V, Salomon S, Valk SJ, Monsef I, Schmaderer C, Wood EM, So-Osman C, Roberts DJ, McQuilten Z, Estcourt LJ, Skoetz N. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database Syst Rev. 2021 Sep 2;9(9):CD013825. doi: 10.1002/14651858.CD013825.pub2.

Public notes

Contacts

Principal investigator

Name

Address

Country

Phone

Fax

Contact person for public queries

Name

Address

Country

Phone

Fax

Contact person for scientific queries

Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT04534725

Trial Review

Did you know?

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04534725